Medication errors with antituberculosis therapy in an inpatient, academic setting: forgotten but not gone
- PMID: 26763664
- DOI: 10.1111/jcpt.12347
Medication errors with antituberculosis therapy in an inpatient, academic setting: forgotten but not gone
Abstract
What is known and objective: Tuberculosis, an infectious disease caused by the bacteria Mycobacterium tuberculosis, has significant public health implications. Despite the decreasing prevalence of tuberculosis cases and the availability of well-established treatment guidelines, errors with antituberculosis medications remain a concern as clinician experience with the infection has waned and the goal of eradicating tuberculosis has remained unfulfilled. Whereas inappropriate use of other anti-infective classes has been extensively studied, the evaluation of medication errors associated with antituberculosis therapy has been limited to a small number of studies conducted more than two decades ago. This study evaluated the prevalence of inpatient medication errors with antituberculosis therapy in patients with suspected or confirmed tuberculosis disease.
Methods: All admitted patients treated with at least one antituberculosis medication between July 2010 and June 2013 were evaluated for inclusion in the retrospective study. Multidrug antituberculosis regimens were reviewed for medication errors, which were categorized as dosing errors, drug interactions, omission of therapy and inappropriate continuation of therapy in the presence of drug toxicity. Appropriate management was determined in accordance with the national guidelines for the treatment of tuberculosis, as well as guidelines on the use of antiretroviral agents for patients with both human immunodeficiency virus (HIV) infection and tuberculosis disease. The impact of infectious diseases and pulmonary consultation on the prevalence of medication errors was also examined.
Results and discussion: More than half of all study patients (44/72, 61%) experienced at least one medication error associated with antituberculosis therapy. Dosing errors were the most common type of medication error identified and were predominantly related to weight-based dosing. Seven dosing errors were related to drug interactions between rifamycins and antiretroviral therapy in HIV-infected patients. Medication error rates were similar between patients receiving consultation from infectious diseases and/or pulmonary specialties and those without consultation. The large majority of antituberculosis medication errors (56/66 errors, 85%) remained uncorrected during the patient's hospital admission.
What is new and conclusion: Medication errors associated with antituberculosis therapy remain a common occurrence in the current clinical practice setting. Greater vigilance when prescribing medications for tuberculosis disease is needed.
Keywords: antituberculosis drugs; medication errors; quality improvement; tuberculosis.
© 2016 John Wiley & Sons Ltd.
Similar articles
-
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.J Assoc Physicians India. 2006 Mar;54:219-34. J Assoc Physicians India. 2006. PMID: 16800350
-
Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.MMWR Recomm Rep. 1998 Oct 30;47(RR-20):1-58. MMWR Recomm Rep. 1998. PMID: 9809743
-
Antiretroviral medication prescribing errors are common with hospitalization of HIV-infected patients.J Antimicrob Chemother. 2014 Jan;69(1):262-7. doi: 10.1093/jac/dkt323. Epub 2013 Aug 16. J Antimicrob Chemother. 2014. PMID: 23956374
-
Tuberculosis and HIV co-infection: a practical therapeutic approach.Drugs. 2006;66(18):2299-308. doi: 10.2165/00003495-200666180-00003. Drugs. 2006. PMID: 17181373 Review.
-
Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.Expert Opin Pharmacother. 2017 Apr;18(6):589-598. doi: 10.1080/14656566.2017.1309023. Epub 2017 Mar 27. Expert Opin Pharmacother. 2017. PMID: 28346018 Review.
Cited by
-
Challenges & Solutions for Recent Advancements in Multi-Drugs Resistance Tuberculosis: A Review.Microbiol Insights. 2023 Jan 30;16:11786361231152438. doi: 10.1177/11786361231152438. eCollection 2023. Microbiol Insights. 2023. PMID: 36741475 Free PMC article. Review.
-
Drug therapy problems for patients with tuberculosis and HIV/AIDS at a reference hospital.Einstein (Sao Paulo). 2019 Aug 22;17(4):eAO4696. doi: 10.31744/einstein_journal/2019AO4696. Einstein (Sao Paulo). 2019. PMID: 31460617 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
